@article {1289,
	title = {Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program},
	journal = {Blood},
	volume = {113},
	year = {2009},
	note = {Pulsipher, Michael A Chitphakdithai, Pintip Miller, John P Logan, Brent R King, Roberta J Rizzo, J Douglas Leitman, Susan F Anderlini, Paolo Haagenson, Michael D Kurian, Seira Klein, John P Horowitz, Mary M Confer, Dennis L U24-CA76518/CA/NCI NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov{\textquoteright}t Research Support, U.S. Gov{\textquoteright}t, Non-P.H.S. Research Support, U.S. Gov{\textquoteright}t, P.H.S. United States Blood Blood. 2009 Apr 9;113(15):3604-11. Epub 2009 Feb 3.},
	month = {39904},
	pages = {3604 - 11},
	edition = {39849},
	abstract = {Limited data are available describing donor adverse events (AEs) associated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelated volunteers. We report results in 2408 unrelated PBSC donors prospectively evaluated by the National Marrow Donor Program (NMDP) between 1999 and 2004. Female donors had higher rates of AEs, requiring central line placement more often (17\% vs 4\%, P95 kg vs <70 kg, OR=1.49). Six percent of donors experienced grade III-IV CALGB toxicities and 0.6\% experienced toxicities that were considered serious and unexpected. Complete recovery is universal, however, and no late AEs attributable to donation have been identified. In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donors will experience bone pain, 1 in 4 will have significant headache, nausea, or citrate toxicity, and a small percentage will experience serious short-term adverse events. In addition, women and larger donors are at higher risk for donation-related AEs.},
	keywords = {*Blood Donors, Adolescent, Adult, Age Distribution, Blood Cell Count, Blood Component Removal / *adverse effects / statistics \& numerical data, Fatigue / epidemiology, Female, Filgrastim / *adverse effects, Follow-Up Studies, Hematopoietic Stem Cell Mobilization / *adverse effects / statistics \&, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Logistic Models, Male, Middle Aged, numerical data, Obesity / epidemiology, Pain / *epidemiology, Prospective Studies, Risk Factors, Sex Distribution, Young Adult},
	issn = {1528-0020 (Electronic) 0006-4971 (Linking)},
	doi = {blood-2008-08-175323 [pii] 10.1182/blood-2008-08-175323},
	author = {Pulsipher,M. A. and Chitphakdithai,P. and Miller,J. P. and Logan,B. R. and King,RJ and Rizzo,J. D. and Leitman,S. F. and Anderlini,P. and Haagenson,M. D. and Kurian,S. and Klein,J. P. and Horowitz,M. M. and Confer,D. L.}
}
